Sentinel lymph node biopsy for melanoma: American society of clinical oncology and society of surgical oncology joint clinical practice guideline

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3313-3324

  Wong, Sandra L ^a   Balch, Charles M ^b   Hurley, Patricia ^d   Agarwala, Sanjiv S ^e   Akhurst, Timothy J ^h   Cochran, Alistair ⁱ   Cormier, Janice N ^c   Gorman, Mark ^j   Kim, Theodore Y ^k   McMasters, Kelly M ^l   Noyes, R Dirk ^m   Schuchter, Lynn M ^f   Valsecchi, Matias E ^g   Weaver, Donald L ⁿ   Lyman, Gary H ^o  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^e St Luke's Cancer Center   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j National Coalition for Cancer Survivorship   (United States)

^k Skagit Valley Regional Cancer Center   (United States)

^l UNIVERSITY OF LOUISVILLE   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^o DUKE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPLETION LYMPH NODE DISSECTION; DISEASE SEVERITY; EMBASE; EVIDENCE BASED PRACTICE; HUMAN; LYMPH NODE DISSECTION; MEDLINE; MELANOMA; PRACTICE GUIDELINE; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS;

HUMANS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84868156599     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2475-3     Document Type: Article

References (37)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206
2. BalchCM, Gershenwald JE, Soong SJ, et al.Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452-9
3. Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009;60:872-5
4. Valsecchi ME, Silbermins D, de Rosa N, et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: A meta-analysis. J Clin Oncol. 2011;29:1479-87
5. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17 (Pubitemid 44465459)
6. Slim K, Nini E, Forestier D, et al. Methodological index for nonrandomized studies (MINORS): Development and validation of a new instrument. ANZ J Surg. 2003;73:712-6 (Pubitemid 37267119)
7. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-83 (Pubitemid 29109331)
8. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759-67 (Pubitemid 24376374)
9. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 1995;5:255-60
10. Uren RF, Howman-Giles R, Thompson JF, et al. Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Res. 1994;4:395-9 (Pubitemid 24381894)
11. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10:676-80 (Pubitemid 40486900)
12. McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86:212-23 (Pubitemid 38880288)
13. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247-58 (Pubitemid 40486764)
14. Sabel MS, Rice JD, Griffith KA, et al. Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy. Ann Surg Oncol. 2012;19:287-93
15. Edge SB, Byrd DR, Compton CC, et al. (eds): AJCC cancer staging manual. 7th edn. New York, NY: Springer
16. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302-11; discussion 311-3
17. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117-26 (Pubitemid 351952257)
18. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48 (Pubitemid 32786276)
19. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34 (Pubitemid 32786275)
20. Gershenwald JE, Mansfield PF, Lee JE, et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (C4 mm) primary melanoma. Ann Surg Oncol. 2000;7:160-5 (Pubitemid 30164687)
21. Ferrone CR, Panageas KS, Busam K, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: Importance of sentinel lymph node status. Ann Surg Oncol. 2002;9:637-45 (Pubitemid 34857980)
22. Balch CM, Gershenwald JE, Soong SJ, et al. Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol. 2011; 104:379-385
23. Gajdos C, Griffith KA, Wong SL, et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer 2009;115:5752-60
24. Essner R, Chung MH, Bleicher R, et al. Prognostic implications of thick (C4 mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol. 2002;9:754-61
25. Carlson GW, Murray DR, Hestley A, et al. Sentinel lymph node mapping for thick (C4 mm) melanoma: Should we be doing it? Ann Surg Oncol. 2003;10:408-15 (Pubitemid 40486939)
26. Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: Is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Oncol. 2002;9:719-22
27. Gutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most important prognostic factor for thick (C4 mm) melanomas. J Dtsch Dermatol Ges. 2008;6:198-203 (Pubitemid 351361065)
28. Scoggins CR, Bowen AL, Martin RC 2nd, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg. 2010;145:622-7
29. Criscione VD, Weinstock MA. melanoma thickness trends in the United States, 1988-2006. J Invest Dermatol. 2010;130:793-7
30. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009;7:308-17
31. Amersi F, Morton DL. The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg. 2007;41:241-56
32. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: A multi-institutional study. Ann Surg Oncol. 2006;13:809-16 (Pubitemid 43727365)
33. Kingham TP, Panageas KS, Ariyan CE, et al. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol. 2010;17:514-20
34. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1,001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051-5 (Pubitemid 19231243)
35. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13:302-9 (Pubitemid 43255912)
36. Geller AC, Miller DR, Lew RA, et al. Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts. Am J Public Health. 1996;86:538-43 (Pubitemid 26125035)
37. Chang AE, Karnell LH, Menck HR: The National Cancer Data Base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade-The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664-78 (Pubitemid 28465486)